预约演示

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

2024-03-25

Nova Nordisk began life in 1923 as the Nordisk Insulin Laboratorium. Based in this building in Denmark, it was the first company to make life-saving insulin commercially available.

As Novo Nordisk expands into heart mediNordiskwe profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

DenNovo NordiskNordisk has agreed to buy Cardior Pharmaceuticals for up to €1bn (US $1bn) to strengthen its cardiovinsulin offerings.

The deal wNovo Nordisk expand its diabeteCardior Pharmaceuticalsings, to include cardiovascular disease treatments. The Danish company has become one of the world's most valuable companies, thanks to its hugely popular weight-loss treatment, Wegovy.

"By welcoming Cardior as a part ofdiabetesrdisk, we will strengthen our pipeline cardiovascular diseaseascular disease where we already have ongoing programmes across all phases of clinical development," Novo said in a statement.

The deal incluCardiordior's heart fNovo Nordiskine CDR132L, currently in clinical trials. It is cardiovascular diseaseng-lasting improvement in heart function, Novo added. The deal is expected to go through in Q2 2024.

Here, we profile NCardiordisheart failurethat has dCDR132Le than any other to further the treatment of diabetes.

Novo Nordisk: A wNovo Nordiskin diabetes treatment & managementdiabetes

Novo Nordisk focuses on serious diabetesdiseases that affect hundreds of millions of people, including types 1 and 2 diabetes, obesity, haemophilia and growth disorders.

Novo Nordiskbegan life in 1923 achronic diseasessulin Laboratorium, and was the first operation to commtypes 1 and 2 diabetesonobesityulhaemophiliahe tegrowth disordersght to Denmark from Canada by August Krogh.

After hearing of the discovery of insulin in 1921, Danish Nobel laureate Krogh and his wife Marie -- a doctor living with diabetes -- travelled to Canada with the goal of producing life-saving insulin in Denmark. In March 1923, the first patients were treated with insulin, marking the beginning of a century of innovation around protein-based treatments for people living with serious chronic diseases.

In 1985, the company launched the insulin, the first insulin pen device. Today, the pen is considered to be a design icon,diabetes company continues to “pioneer delivery systems that improve quinsulinf life and make managing chronic diseases easier”, it says.insulin chronic diseases

In 1989, Nordisk merged with Novo, which had been set up in 1925 by brothers Harald and Thorvald Pedersen, former employees of Nordisk.chronic diseases

Both NovoNordiskrdisk had estNovoshed diabetes hospitals in Denmark to provide specialised diabetes care and lifestyle guidanceNordiskgaining a better understanding of patients’ needs. In 1992, the two hospitals merged, to become the Steno Diabetes Center in Copenhagen, which remains at the forefront of diabetes treatment.

Novo Novoisk sNordiskdraws upon insighdiabetespatients and partners “to transform bold ideadiabetesife-saving and preventive medicines”.Diabetes diabetes

Novo Nordiskmake long-term investments in ground-breaking treatments and technologies, including curative stem cell-based therapies, to “continually advance the development of medical devices and digital health solutions”.

Novo Nordisk in statistics:

Novo Nordisk amount of the world’s insulin supply

Manufactures over 600 million insulinsulin

Over 36 million people use theinsuliny’s diabetes care products

Conduct clinical trials in over 50 countrdiabetes

In August 2023, Novo Nordisk partnered with Kakao Healthcare to develop its diabetes management service with AI technology. Kakao is the digital healthcare business of South Korean internet company Kakao Corporation.

The companies siNovo Nordiskandum of understanding to open a smart healthcardiabetese to assist patients with diabetes.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构